Animal model of oculopharyngeal muscular dystrophy

Acta Myologica

Volumn 24, Issue 2, 2005, Pages 84-88

  Uyama, Eiichiro ^a   Hino, H ^a,b   Araki, K ^b   Takeya, M ^b   Uchino, M ^a   Yamamura, K ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Model mouse; Oculopharyngeal muscular dystrophy; PABPN1

Indexed keywords

ALANINE; BINDING PROTEIN; NUCLEAR PROTEIN; PROTEIN POLY A BINDING PROTEIN NUCLEAR 1; UNCLASSIFIED DRUG;

AGING; CELL NUCLEUS INCLUSION BODY; CONFERENCE PAPER; ELECTRON MICROSCOPY; EYELID MUSCLE; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PHENOTYPE; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SKELETAL MUSCLE; TRANSGENIC ANIMAL;

ACTINS; ALANINE; ANIMALS; DISEASE MODELS, ANIMAL; INCLUSION BODIES; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; POLY(A)-BINDING PROTEIN II;

EID: 33344467144     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Taylor EW, Progressive vagus-glossopharyngeal paralysis with ptosis: a contribution to the group of family disease. J Nerv Ment Dis 1915;42:129-39.
2. Victor M, Hayes R, Adams RD. Oculopharyngeal muscular dystrophy: a familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Engl J Med 1962;267:1267-72.
3. Bouchard JP. Andre Barbeau and the Oculopharyngeal muscular dystrophy in French Canadaand North America. Neuromusc Disord 1997;7:S5-S11.
4. Tomé FM, Fardeau M. Nuclear inclusions in Oculopharyngeal dystrophy. Acta Neuropathol 1980;49:85-7.
5. Tomé FM. Fardeau M. Oculopharyngeal muscular dystrophy. In Engel AG, Franzini-Armstrong C, (eds), Myology, 2nd ed. New York: McGraw-Hill; 1994, pp. 1233-45.
6. Uyama E, Nohira O, Chateau D, et al. Oculopharyngeal muscular dystrophy in two unrelated Japanese families. Neurology 1996;46:773-8.
7. Tome FMS, Chateau D, Helbling-Leclerc A, Fardeau M. Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromusc Disord 1997;7:S63-S69.
8. Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998;18:164-7.
9. Scacheri PC, Garcia C, Hébert R, Hoffman EP. Unique PABP2 mutations in "Cajuns" suggest multiple founders of oculopharyngeal muscular dystrophy in populations with French ancestry. Am J Med Genet 1999;86:477-81.
10. Nakamoto M, Nakano S, Kawashima S, et al. Unequal crossing-over in unique PABP2 mutations in Japanese patients. Arch Neurol 2002;59:474-7.
11. van der Sluijs BM, van Engelen BG, Hoefsloot LH. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene. Hum Mutat 2003;21:553.
12. Robinson DO, Hammans SR, Read SP, Sillibourne J. Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism. Hum Genet 2005;116:267-71.
13. 9 mutation in the PABP2 gene. Neurology 2000;55:1267-70.
14. Becher MW, Morrison L, Davis LE, et al. Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 2001;286:2437-40.
15. Uyama E, Tsukahara T, Goto K, et al. Nuclear accumulation of expanded PABP2 gene product in oculopharyngeal muscular dystrophy. Muscle Nerve 2000;23:1549-54.
16. Pou Serradell A, Lloreta Trull J, Corominas Torres JM, et al. Oculopharyngeal muscular dystrophy: study of patients from seven Spanish families with different GCG expansions in PABP2 gene [in Spanish]. Neurologia 2004;19:239-47.
17. Mirabella M, Silvestri G, de Rosa G, et al. GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy. Neurology 2000;54:606-14.
18. Hill ME, Greed GA, McMullan TFW, et al. Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain 2001;124:522-26.
19. Kühn U, Wahle E. Structure and function of poly(A) binding proteins. Biochim Biophys Acta 2004;1678:67-84
20. Calado A, Tomé FMS, Brais B, et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000;9:2321-28
21. Uyama E, Goto K, Tsukahara T, et al. Oculopharyngeal muscular dystrophy: phenotype/genotype relationship in Japanese families. Neuromusc Disord 1999;9:512
22. Tokutake T, Ikeuchi T, Tanaka K, Onodera O, Nishizawa M. A late-onset case of oculopharyngeal muscular dystrophy carrying a (GCG)8 repeat expansion in the PABP1 gene [in Japanese]. Rinsho Shinkeigaku 2005;45:437-40
23. Schober R, Kre, W, Grahmann F, et al. Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. Neuropathology 2001;21:45-52.
24. Minami N, Ikezoe, K, Kuroda H, et al. Oculopharyngodistal myopathy is genetically heterogeneous and most cases are distinct from oculopharyngeal muscular dystrophy. Neuromusc Disord 2001;11:699-702.
25. Blumen SC, Brais B, Korczyn AD, et al. Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann Neurol 1999;46:115-8.
26. Brais B. Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease. Cytogenet Genome Res 2003;100:252-60
27. Ross AC. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine mechanism for glutamine-repeat neurodegenerative disease? Neuron 1997;19:1147-50.
28. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002;296:1991-5.
29. Calado A, Tomé FMS, Brais B, et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000;9:2321-8.
30. Uyama E, Tsukahara T, Goto K, et al. Nuclear accumulation of expanded PABP2 gene product in oculopharyngeal muscular dystrophy. Muscle Nerve 2000;23:1549-54.
31. Becher MW, Kotzuk JA, Davis LE, Bear DG. Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2. Ann Neurol 2000;48:812-5.
32. Shanmugam V, Dion P, Rochefort D, Laganiere J, Brais B, Rouleau GA. PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. Ann Neurol 2000;48:798-802.
33. Bao YP, Cook LJ, O'Donovan D, Uyama E, Rubinsztein DC. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J Biol Chem 2002;277:12263-9.
34. Fan X, Dion P, Laganiere J, Brais B, Rouleau GA. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. Hum Mol Genet 2001;10:2341-51.
35. Abu-Baker A, Messaed G, Laganiere J, et al. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet 2003;12;:2609-23.
36. Bao YP, Sarkar S, Uyama E, Rubinsztein DC. Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. Med Genet 2004;41:47-51.
37. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-10.
38. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 2005;14:679-91.
39. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005;14:2749-55.
40. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657-63.
41. Klement LA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998;95:41-53.
42. Schilling G, Wood JD, Duan K, et al. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 1999;24:275-86.
43. Rubinsztein DC. Lessons from animal models of Huntington's disease. Trends Genet 2002;18:202-9.
44. Hino H, Araki K, Uyama E, et al. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum Mol Genet 2004;13:181-90.
45. Dion P, Shanmugam V, Gaspar C, et al. Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol Dis 2005:18:528-36.
46. Davies JE, Wang L, Garcia-Oroz L, et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 2005;11:672-7.